ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Sangamo Therapeutics Inc

Sangamo Therapeutics Inc (SGMO)

0.6247
0.0213
(3.53%)
Closed March 27 04:00PM
0.64
0.0153
( 2.45% )
Pre Market: 08:21AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.64
Bid
0.63
Ask
0.6494
Volume
4,663
0.00 Day's Range 0.00
0.2911 52 Week Range 1.8199
Market Cap
Previous Close
0.6247
Open
-
Last Trade Time
08:21:11
Financial Volume
-
VWAP
-
Average Volume (3m)
2,417,979
Shares Outstanding
178,906,350
Dividend Yield
-
PE Ratio
-0.58
Earnings Per Share (EPS)
-1.07
Revenue
111.3M
Net Profit
-192.28M

About Sangamo Therapeutics Inc

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemoph... Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Sangamo Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SGMO. The last closing price for Sangamo Therapeutics was $0.62. Over the last year, Sangamo Therapeutics shares have traded in a share price range of $ 0.2911 to $ 1.8199.

Sangamo Therapeutics currently has 178,906,350 shares outstanding. The market capitalization of Sangamo Therapeutics is $110.92 million. Sangamo Therapeutics has a price to earnings ratio (PE ratio) of -0.58.

SGMO Latest News

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the...

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Data from novel proprietary neurotropic adeno-associated virus (AAV) delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier (BBB) penetration in non-human primates (NHPs...

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Novel AAV capsid engineered by Sangamo showed robust penetration of blood-brain barrier (BBB) and widespread transgene expression throughout brain in non-human primates (NHPs) following...

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

- U.S. Food and Drug Administration (FDA) advises that a single study with up to 25 patients, in combination with confirmatory evidence, may be acceptable pathway to Biologics License Application...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2-23.80952380950.840.97820.59133845300.70721916CS
4-0.47-42.34234234231.111.190.59122952450.8319882CS
120.102219.00334696910.53781.480.3924179790.84395693CS
260.0396.489184692180.6011.480.291122202400.6600859CS
52-1.1-63.21839080461.741.81990.291121462090.95266486CS
156-11.34-94.657762938211.9812.850.291116250553.79667619CS
260-8.45-92.95929592969.0919.430.291117318306.77710354CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 20.2688
(326.71%)
1.68M
XLOXilio Therapeutics Inc
$ 2.08
(225.51%)
7.31M
BCGBinah Capital Group Inc
$ 18.913
(99.08%)
177.54k
PIKKidpik Corporation
$ 5.84
(78.59%)
2.47M
AKANAkanda Corporation
$ 0.2385
(44.63%)
5.55M
GMDAGamida Cell Ltd
$ 0.0474
(-19.93%)
6.8M
NCNANuCana PLC
$ 0.2468
(-19.52%)
91.64k
WAVDWaveDancer Inc
$ 2.93
(-18.61%)
11
INOInovio Pharmaceuticals Inc New
$ 10.65
(-18.27%)
236
UGROUrban Gro Inc
$ 1.50
(-17.36%)
4.41k
KTRAKintara Therapeutics Inc
$ 0.1129
(26.15%)
17.06M
AKBAAkebia Therapeutics Inc
$ 2.4909
(11.20%)
10.95M
CISSC3is Inc
$ 0.0344
(-9.95%)
10.05M
XLOXilio Therapeutics Inc
$ 2.10
(228.64%)
7.34M
GMDAGamida Cell Ltd
$ 0.047
(-20.61%)
6.81M

SGMO Discussion

View Posts
jondoeuk jondoeuk 6 days ago
They have had countless secondaries over the years, but never an approved therapy. This company has been nothing more than a capital consuming beast created by Edward Lanphier, and he as well as others, mainly management taking shareholders to the cleaners, while they live in luxury! https://finance.yahoo.com/news/sangamo-therapeutics-announces-pricing-24-120500032.html
šŸ‘ļø0
work-n-hard work-n-hard 6 days ago
https://www.nasdaq.com/press-release/sangamo-therapeutics-announces-pricing-of-%2424.0-million-registered-direct-offering
šŸ‘ļø0
jondoeuk jondoeuk 6 days ago
From the 10-K: ''Based on our current operating plan, our cash, cash equivalents and marketable securities as of December 31, 2023 are expected to allow us to meet our liquidity requirements only into the third quarter of 2024. Although we have been actively seeking, and continue to actively seek, substantial additional capital, including through public or private equity or debt financing, royalty financing or other sources, such as strategic collaborations and other direct investments in our programs, we have been unsuccessful in securing any such additional capital to date. As a result, we have explored, and continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders.''
šŸ‘ļø0
AliasUser1 AliasUser1 1 week ago
Bought some today. Risk/Reward is definitely worth it here.
šŸ‘ļø0
DNORWOOD DNORWOOD 3 weeks ago
Happy March another day another dollar close. Cheers.
šŸ‘ļø0
The Canes The Canes 4 weeks ago
It was critical! I hate reverse splits. That's where we were headed if we didn't hold a buck today. BRAVO!
šŸ‘ļø0
DNORWOOD DNORWOOD 4 weeks ago
Hey we close above a dollar over 10 days. Yes.
šŸ‘ļø0
DNORWOOD DNORWOOD 4 weeks ago
Today is our day. Iā€™m long SGMO and ATUS and ELTP and PLCE
šŸ‘ļø0
DNORWOOD DNORWOOD 4 weeks ago
Spreading the word. Buy SGMO. Hitting up Reddit we need them behind us. Cheers.
šŸ‘ļø0
The Canes The Canes 4 weeks ago
As I said there won't be any announcement regarding the earnings until after we close tomorrow. It's critical we stay above a dollar for 10 straight days. So tomorrow I expect the shorts to try and drive us below a dollar near the close. I have lots of ammo ready to buy the offer to fight the bastards off! You do the same amigo!
šŸ‘ļø0
DNORWOOD DNORWOOD 4 weeks ago
Big buyers. Are earning today????
šŸ‘ļø0
DNORWOOD DNORWOOD 4 weeks ago
You are correct. We are good.
šŸ‘ļø0
The Canes The Canes 4 weeks ago
We'll be good when we attain compliance after the close on Thursday. God willing the shorts don't upend that! Then and only then will the fool of a CEO announce the earnings call.
šŸ‘ļø0
DNORWOOD DNORWOOD 4 weeks ago
We are good
šŸ‘ļø0
DNORWOOD DNORWOOD 1 month ago
We have some good news coming. Cheers.
šŸ‘ļø0
DNORWOOD DNORWOOD 1 month ago
Good news coming my friends. Cheers.
šŸ‘ļø0
DNORWOOD DNORWOOD 1 month ago
I think early earnings next week maybe Monday. Looking good and feeling good.
šŸ‘ļø0
AliasUser1 AliasUser1 1 month ago
Could turn out to be good and go to 5+ somewhat quickly if things develop correctly. Cash burn will be pretty much cut in half this year too
šŸ‘ļø0
DNORWOOD DNORWOOD 1 month ago
I smell buyout or merger. Here we go. Volume is off the charts. All institutions and backdoor deals.
šŸ‘ļø0
DNORWOOD DNORWOOD 1 month ago
Here we
Go. Cheers.
šŸ‘ļø0
DNORWOOD DNORWOOD 1 month ago
Is Pfizer buying us out or just a friend?!?!????? Cheers.
šŸ‘ļø0
DNORWOOD DNORWOOD 1 month ago
We are going to the moon. Earnings coming and much much more. Cheers.
šŸ‘ļø0
Monksdream Monksdream 1 month ago
SGMO under $2
šŸ‘ļø0
Liam859 Liam859 1 month ago
$SGMO $1.45 busting ignore the noise
šŸ‘ļø0
trendzone trendzone 1 month ago
Earlier in the week some total creep manipulators were keeping it pinned at $0.73, if the were shorting they got their butt handed to them, if they were just some dumbass seller, they look like a total fool right now,with it at $1.35, corrupt Wall Street BS as usual, the biggest criminals walking on the earth today, steel from the public and give to their kind.
šŸ‘ļø0
Liam859 Liam859 1 month ago
$.82 the run begins
šŸ‘ļø0
Liam859 Liam859 3 months ago
$SGMO $0.55 buying it up here
šŸ‘ļø0
Penny Trades Penny Trades 4 months ago
Yeah maybe I should shirt the stock like you did, good idea, could have made big bucks lol
šŸ‘ļø0
Monksdream Monksdream 5 months ago
SGMO new 52 week low
šŸ‘ļø0
Monksdream Monksdream 6 months ago
I quite agree with your assessment of clinical stage bio companies as expensive experiments.
Out of curiosity I checked the reverse stock split history for Sangamo and came up with zero, which I found interesting.
Ever since Amgen went public in 1984 investors have placed high hopes on the possibility of hitting the Big One.

The biotech, biomed, medical device sector is actually the largest sector in terms of available public traded companies in which one
can invest. More go public every week.
The stock has certainly experienced some dramatic ups and downs since 2000

šŸ‘ļø0
Monksdream Monksdream 6 months ago
SGMO new 52 week low
šŸ‘ļø0
NY1972 NY1972 6 months ago
Most bios are expensive experiments done by expensive PhDs. They are Wall St. shows nobody should stick around for the endings.
šŸ‘ļø0
jondoeuk jondoeuk 6 months ago
Over 28 years with no success, allowing others to overtake them, while they created an unsustainable infrastructure. They couldn't even license their AAV capsids or ZFP-TFs, instead having to settle for a nominal "evaluation agreements" with Prevail and Chroma.

Worse still, have around a year of cash on hand unless they decide to address their costs. Does anyone know when the company plans on breaking even? Will it be in '26 or '27 if their haemophilia therapy is approved in '25? Also, they will need to rise, and with the current price it's going to be (extremely) dilutive. If the therapy isn't approved, I don't see how the company isn't toast.
šŸ‘ļø0
Monksdream Monksdream 6 months ago
SGMO new 52 week low
šŸ‘ļø0
Monksdream Monksdream 6 months ago
SGMO new 52 week low
šŸ‘ļø0
The Canes The Canes 7 months ago
It was uplifting and important to close at a dollar yesterday.
šŸ‘ļø0
Monksdream Monksdream 7 months ago
SGMO new 52 week low
šŸ‘ļø0
Monksdream Monksdream 7 months ago
SGMO new 52 week low
šŸ‘ļø0
Penny Trades Penny Trades 7 months ago
Time to buy!!!
šŸ‘ļø0
Monksdream Monksdream 7 months ago
SGMO new 52 week low
šŸ‘ļø0
Monksdream Monksdream 7 months ago
SGMO new 52 week low
šŸ‘ļø0
seve333 seve333 8 months ago
test
šŸ‘ļø0
AJ Freely AJ Freely 8 months ago
$SGMO - Up 10.5% Pre-Market/ Current Price $1.44
Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
šŸ‘ļø0
The Canes The Canes 12 months ago
I'm not ready to put a fork in it yet. I think there's still a considerable pulse.
šŸ‘ļø0
jondoeuk jondoeuk 1 year ago
The company is essentially dead.
šŸ‘ļø0
jondoeuk jondoeuk 1 year ago
A double whammy https://www.marketscreener.com/quote/stock/SANGAMO-THERAPEUTICS-INC-10811/news/SANGAMO-THERAPEUTICS-INC-Termination-of-a-Material-Definitive-Agreement-form-8-K-43276781/
šŸ‘ļø0
jondoeuk jondoeuk 1 year ago
Are you familiar with EDIT? How well they are they doing after winning a patent fight with CRSP?
šŸ‘ļø0
TechandBio TechandBio 1 year ago
Deep Pipeline blockbuster potential across the board.

Major partnerships.

Lots of headwinds entering 2023 Looking for substantial gains from here.

Chart just turned bullish.


$SGMO
šŸ‘ļø0
MWM MWM 3 years ago
šŸ‘ļø0
MWM MWM 3 years ago
This is an excellent read on SGMO

https://t.co/XXLJtZOpQI
šŸ‘ļø0

Your Recent History

Delayed Upgrade Clock